MPM Bioimpact LLC acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 559,547 shares of the company's stock, valued at approximately $3,452,000. MPM Bioimpact LLC owned 0.99% of Design Therapeutics at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of DSGN. Invesco Ltd. acquired a new position in Design Therapeutics during the fourth quarter worth $71,000. China Universal Asset Management Co. Ltd. acquired a new position in Design Therapeutics during the fourth quarter worth $74,000. Kennedy Capital Management LLC acquired a new position in Design Therapeutics during the fourth quarter worth $88,000. Intech Investment Management LLC acquired a new position in Design Therapeutics during the fourth quarter worth $109,000. Finally, Wells Fargo & Company MN grew its holdings in Design Therapeutics by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock worth $114,000 after acquiring an additional 4,013 shares during the period. Institutional investors and hedge funds own 56.64% of the company's stock.
Design Therapeutics Stock Down 1.7%
DSGN stock traded down $0.06 on Monday, reaching $3.45. 17,711 shares of the company's stock were exchanged, compared to its average volume of 186,871. The stock has a fifty day moving average of $3.88 and a 200-day moving average of $4.88. Design Therapeutics, Inc. has a twelve month low of $2.60 and a twelve month high of $7.77. The firm has a market cap of $195.85 million, a PE ratio of -4.06 and a beta of 1.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, equities research analysts predict that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Design Therapeutics Company Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
